Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class A beta-lactamases are a prominent family of bacterial enzymes that serve as a primary mechanism of resistance against beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems [1, 7]. These enzymes function as serine hydrolases, utilizing a conserved active-site serine residue to catalyze the nucleophilic attack and subsequent hydrolysis of the four-atom beta-lactam ring, thereby deactivating the antibiotic's ability to inhibit bacterial cell wall synthesis [4, 8]. The family is highly diverse and includes widely distributed narrow-spectrum penicillinases like TEM-1 and SHV-1, as well as clinically significant extended-spectrum beta-lactamases (ESBLs) and potent carbapenemases such as KPC [2, 5, 10]. Class A beta-lactamases are frequently encoded on mobile genetic elements like plasmids and transposons, facilitating their rapid horizontal spread among Gram-negative pathogens, particularly Enterobacterales [1, 3]. In clinical practice, these enzymes are the primary targets for beta-lactamase inhibitors, which are co-administered with antibiotics to neutralize the enzyme and restore the therapeutic efficacy of the antimicrobial treatment [9, 11].
Beta-lactamase inhibitors function by binding to the active-site serine of the enzyme, either as suicide inhibitors that form an irreversible covalent bond (e.g., clavulanic acid, tazobactam) or as high-affinity reversible inhibitors (e.g., avibactam, vaborbactam), preventing the hydrolysis of co-administered beta-lactam antibiotics [11, 15].
14 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class A beta-lactamase (Class A BLA).